Abbott finally enters the leadless pacemaker fray
Remember Nanostim? It’s back – in a modified form, sold by a different company, and under another name.
How Covid failed to derail the FDA
Average US review times match absolute approval numbers in remaining unaffected by the Covid pandemic.
